Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ACTINOGEN-MEDICAL-LIMITED-10355426/news/Actinogen-Medical-Limited-Announces-Optimization-of-XanaMIA-Phase-2b-Trial-in-Patients-with-Mild-to-44942483/?utm_source=whatsapp&utm_medium=social&utm_campaign=share